The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Towards A Better Paradigm for Head and Neck Cancer Treatment Applying Artificial Intelligence. HNC-TACTIC.
Official Title: Towards A Better Paradigm for Head and Neck Cancer Treatment Applying Artificial Intelligence: an International Cohort Study of Electronic Health Records. HNC-TACTIC.
Study ID: NCT05117775
Brief Summary: This will be an international, multicenter, retrospective, observational, and data-driven study using secondary data captured in EHRs. The extraction of the data captured in the EHRs will be performed with SAVANA's EHRead®, an innovative data-driven system based on Natural Language Processing (NLP) and machine learning. For all patients, the Index Date is defined as the timepoint within the study period when they fulfill ALL inclusion criteria and no exclusion criteria. Follow-up comprises the period between Index Date and the last EHR available within the study period. Additional variable-specific time windows may be considered to optimize data collection.
Detailed Description: The present study aims to describe the clinical characteristics of patients with HNSCC in a real-world setting by analyzing readily available information in the Electronic Health Records (EHRs). This study will gain a deep insight of the clinical characteristics and real-world outcomes of patients with all stages (early, locally advanced, and metastatic) of HNSCC. It will focus on developing two predictive models to apply in the clinical setting, one for electing patients with high-risk of recurrence after radical treatment, and the second one for selecting recurrent or metastatic patients who could benefit from immunotherapy. To achieve the proposed study objectives we will use SAVANA´s EHRead® (11-15), a technology that applies Natural Language Processing (NLP) (16) and machine learning to extract, organize, and analyze the unstructured clinical information jotted down by health professionals in patients' EHRs. Primary objectives * To develop a predictive model based on dynamic risk stratification (DRS) for the risk of recurrence or disease progression following a primary curative treatment in HNSCC patients with early and locally advanced disease. * To develop a predictive model based on dynamic risk stratification (DRS) aimed at identifying patients' features that predict long-term survival after immunotherapy in recurrent and metastatic HNSCC patients. Secondary objectives * To describe median OS by primary tumor location (oral cavity, oropharynx, larynx, and hypopharynx) in HNSCC patients after stratification for prognostic factors, including tumor stage and treatment. * To describe the demographics, clinical characteristics, and treatment of patients with HNSCC in early and locally advanced stages of the disease. * To describe the patterns of follow-up in patients with HNSCC in early and locally advanced stages of the disease. * Departments in charge * Number of visits * Imaging and anatomopathological tests * Recurrence detected by physical examination. * To evaluate the impact of treatments on patients with locally advanced stages of the disease. * Patients' early and late toxicity to the treatment, comparing between radiotherapy (+/-cisplatin or cetuximab) vs surgery and post-operative r\< radiotherapy (+/- cisplatin). * Healthcare resource utilization (HCRU), including medical visits, diagnostics, and hospitalizations. * To compare OS in locally advanced HNSCC patients (including both HPV+ and HPV- oropharyngeal patients) treated with cisplatin-radiotherapy vs cetuximab-radiotherapy and treated with surgery vs. conservative treatment. * To compare the demographic and clinical characteristics of exceptional responders and poor responders (based on recurrence and long-term survival). This analysis will be performed independently for HPV+ and HPV- oropharyngeal patients.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Savan Research S.L, Madrid, , Spain
Name: John Almeida
Affiliation: University Health Network and Mount Sinai Hospital
Role: STUDY_CHAIR
Name: Sujith Baliaga
Affiliation: Ohio State University
Role: STUDY_CHAIR
Name: David Casadevall
Affiliation: Medsavana S.L
Role: STUDY_CHAIR
Name: Melvin Chua
Affiliation: National Cancer Centre, Singapore
Role: STUDY_CHAIR
Name: Andreas Dietz
Affiliation: University Hospital of Leipzig
Role: STUDY_CHAIR
Name: Robert Ferris
Affiliation: UPMC Hillman Cancer Center
Role: STUDY_CHAIR
Name: Raul Giglio
Affiliation: Hopital Ángel H. Roffo de Buenos Aires
Role: STUDY_CHAIR
Name: Chris Holsinger
Affiliation: Stanford University
Role: STUDY_CHAIR
Name: Kate Hutcheson
Affiliation: M.D. Anderson Cancer Center
Role: STUDY_CHAIR
Name: Husham Menhanna
Affiliation: Institute of Head and Neck Studies and Education (InHANSE)
Role: STUDY_CHAIR
Name: Pablo Parente
Affiliation: Hospital HM Rosaleda
Role: STUDY_CHAIR
Name: Sandro Porceddu
Affiliation: Queensland Institute of Medical Research (QIMR)
Role: STUDY_CHAIR
Name: Miren Taberna
Affiliation: Medsavana S.L
Role: PRINCIPAL_INVESTIGATOR
Name: Christian Simon
Affiliation: CHUV Lausanne
Role: STUDY_CHAIR